

# Anne Santerre Henriksen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5886485/publications.pdf>

Version: 2024-02-01

7

papers

106

citations

1684188

5

h-index

1588992

8

g-index

8

all docs

8

docs citations

8

times ranked

122

citing authors

#	ARTICLE	IF	CITATIONS
1	In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany. Journal of Global Antimicrobial Resistance, 2022, 28, 12-17.	2.2	3
2	<i>In vitro</i> activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19). JAC-Antimicrobial Resistance, 2022, 4, dlac030.	2.1	2
3	<i>In vitro</i> activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France. JAC-Antimicrobial Resistance, 2021, 3, dlab081.	2.1	10
4	Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clinical Microbiology and Infection, 2021, 27, 671-686.	6.0	54
5	Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates. Journal of Antimicrobial Chemotherapy, 2019, 74, 3453-3461.	3.0	15
6	Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015. Infection and Drug Resistance, 2018, Volume 11, 1309-1320.	2.7	6
7	Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1653-1659.	2.9	13